75%Confidence
0Views
FDASource
2026-03-07Date
Summary
Asteria Health's testosterone pellets face a Class II recall for potential metal particulate contamination, raising safety concerns that could lead to regulatory action and reduced consumer trust. This may impact the compounding pharmacy market and increase scrutiny on hormone replacement therapies.
Actionable: Consider reducing exposure to compounding pharmacy stocks until contamination investigations are resolved.
AI Confidence: 75%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 100 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC:79559-1100-32.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now